24 results about "Dl-Epinephrine" patented technology

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The utility model discloses epinephrine hydrochloride liquid medicine production equipment, and relates to the technical field of liquid medicine filling. Comprising a first nitrogen gas curtain arranged at a post-filling station, a preheating station and a wire drawing and sealing station respectively, the first nitrogen gas curtain is communicated with a nitrogen gas source, and the nitrogen gas source is communicated with a second nitrogen gas curtain and a feeding barrel; the second nitrogen gas curtain is arranged at the weighing station, and the feeding barrel is arranged at the liquid medicine filling station; the first nitrogen gas curtain is used for reducing residual oxygen in the ampoule bottle from operation after filling to operation before wire drawing and sealing; the second nitrogen gas curtain is used for reducing residual oxygen in the weighing barrel; and the feeding barrel is used for batching under the protection of nitrogen. According to the utility model, the second nitrogen gas curtain is used for reducing residual oxygen in the weighing barrel, and the feeding barrel is used for batching under the protection of nitrogen, so that the residual oxygen of raw materials is effectively reduced; and meanwhile, through the first nitrogen gas curtain, the time for exposing the ampoule bottle in the air is greatly shortened, and residual oxygen in the ampoule bottle which runs from the time after filling to the time before wire drawing and sealing is effectively reduced.

A pharmaceutical aerosol formulation containing pre-micronized epinephrine, a co-solvent ethanol, a surfactant polysorbate 80, and a propellant trans-1, 3, 3, 3-tetrafluoropropene (HFO-1234ze (E)) for use in a pressurized metered dose inhaler is described. The formulations provide efficient delivery of pre-micronized epinephrine particles into the respiratory tract of a patient, and have the advantages of high therapeutic efficacy, improved safety, and low global warming potential (GWP) affecting the environment.

Self-administered pharmaceutical compositions of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are comparable to those compositions administered by a health care professional and by intramuscular injection.

The invention provides carbon-14-labeled epinephrine and a preparation method thereof, carbon-14-labeled noradrenaline and a preparation method thereof, and belongs to the field of radioactive chemistry. The invention provides a carbon-14 labeled epinephrine or a carbon-14 labeled noradrenaline, wherein the carbon-14 label is located at the a position of the benzene ring of the epinephrine or the noradrenaline. According to the present invention, the epinephrine and the noradrenaline are subjected to carbon-14 labeling, such that the metabolite ratio can be quantitatively analyzed, the dynamic conversion rule of the metabolite in the human body can be revealed, the drug administration scheme can be easily optimized, the toxicological mechanism can be easily clarified, the theoretical basis can be provided for the clinical safety application, and the scientific development of the first-aid drug can be promoted.

Pharmaceutical compositions of epinephrine and prodrugs thereof are described, as well as compositions having enhanced permeability of active ingredients for administration at specific residence times.

The present invention provides a method for determining the amount of one or more of one or more noradrenaline (NE), epinephrine (E), and dopamine (D) in a sample using mass spectrometry. The methods generally involve ionizing one or more of NE (or derivatized NE), E (or derivatized E), and D (or derivatized D) in a sample, and detecting and quantifying the amount of ions to determine the amount of one or more of NE, E, and D in the sample.

The present invention relates to a contour injection composition, and more specifically, is characterized by an injection composition comprising a solvent, aminophylline, procaine, epinephrine, and hyaluronidase, the injection composition comprising, on the basis of the entire composition, 500 to 700 IU units hyaluronidase, and 0.05 to 0.15% (w / v) aminophylline, 0.01 to 0.03% (w / v) procaine, 0.001 to 0.006% (w / v) epinephrine, and the remainder the solvent, wherein the solvent is half saline and distilled water. According to the present invention, the injection composition has excellent fat decomposition and fat destruction effects and cellulite reduction effect, as well as effect in improving a circulation function, thereby reducing subcutaneous fat in a desired area, and having the advantages not only of improving body and facial lines by improving elasticity, but also not causing side effects such as redness, itchiness, swelling, skin depression, and skin sagging.

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

It relates to novel formulations of epinephrine that comprise polyoxymethylene alkyl ethers as a permeation enhancer, methods of administering the formulation, and uses thereof.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The present disclosure relates to novel formulations of epinephrine comprising polyoxyethylene alkyl ethers as penetration enhancers, methods of administration of the formulations, and uses thereof.

The present invention relates to a syringe and medical kit, which allow for doses of epinephrine of 0.15 mg or 0.15 mL, 0.3 mg or 0.3 mL, and 0.5 mg or 0.5 mL, the most commonly prescribed doses which are utilized today in treating anaphylaxis or other allergic reactions. Currently, existing syringes may include many markings of ten or more dosages. Although these prior art syringes are useful, it is difficult to use them for a patient who must quickly identify a correct dose level among many other marks. The above problem can be addressed by a syringe design which has only a few dosage markings, which correspond to commonly used standard dosages for children and adults. When used with a standard concentration of 1:1000 epinephrine solution, such a device can rapidly provide a known quantity of medicine to a patient who is in urgent need of it.

Methods of treating an allergic symptom by oral administration of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are improved or comparable to those compositions administered by intramuscular injection.

The application discloses a compound solid preparation containing phenylephrine hydrochloride and a preparation method thereof, which is a solid preparation prepared by taking phenylephrine hydrochloride, acetaminophen and chlorpheniramine maleate as active ingredients, and taking a coating agent, a binder, a filler, a lubricant and the like as auxiliary materials, and the solid preparation is a tablet. Since phenylephrine hydrochloride can be degraded in the presence of oxygen, aldehyde, certain acids and metals, the phenylephrine hydrochloride is coated with a coating agent, and then mixed with other raw and auxiliary materials to prepare granules by using a dry granulation method, and finally, the granules are compressed to obtain the tablet.

The invention provides a stable, pharmaceutical formulation comprising epinephrine or a pharmaceutically acceptable salt thereof. The formulation includes an organic acid, a tonicity agent, and water, has a pH of about 3.0 to about 3.6, and is substantially free of a conjugate base of the organic acid.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

A sterile storage stable ready-to-inject epinephrine composition contained within a flexible container and packaged within a secondary container, the composition including an aqueous pharmaceutically acceptable carrier containing epinephrine and a metal ion chelator, the epinephrine being present in a concentration of equal to or less than 0.07 mg / mL, substantially all of the epinephrine being an R-isomer, the composition having a pH of between 3.5-4.7, and the composition having, after storage of at least one month at 25° C., total impurities of equal or less than 0.7% and equal or less than 4% S-isomer content.

A sensor that employs rationally designed polymeric and biopolymeric matrices by incorporating and maximizing key functional groups while eliminating interfering functional groups. A series of polymers and biopolymers designed with high aromaticity and negative charges to attract and detect monoamine redox active neurotransmitters (i.e., serotonin, dopamine, epinephrine, and norepinephrine) are disclosed and used in the disclosed sensor. Notably, these polymers and biopolymers are designed in such a way as to enable facile deposition onto surfaces either spontaneously or through quick electrodeposition. Such sensors typically employ a significantly reduced amount of PEDOT and can be used as a neurotransmitter sensor that can be used to monitor and / or diagnosis mood disorders, sleep disorders, cognition deficits, metabolite levels, neurological disorders; therapeutics level monitoring and / or identification. The aforementioned sensor can be wearable, implantable, multiuse or single use.

Pharmaceutical compositions of epinephrine and its prodrugs are described and the compositions having enhanced active component permeation properties are described as being administered with specific residence times.

Self-administered pharmaceutical compositions of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are comparable to those compositions administered by a health care professional and by intramuscular injection.